A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Key facts
- Where
- Ann Arbor, Bellaire, Birmingham, Fort Gratiot, Fountain Valley, Glenview, Hollywood, Houston, Indianapolis, Jacksonville, Las Vegas, Miami, Murfreesboro, Norfolk, Omaha, Pflugerville, Plano, Portland, Rockville, San Diego, St. Petersburg, The Bronx, Thousand Oaks, and Troy, United StatesSee the 24 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT07431177, who can take part
Where in United States
- Uni Of Michigan Health SystemAnn Arbor, United StatesContact: Nicole MahnTaking people
- Bellaire Dermatology AssociatesBellaire, United StatesContact: Luis Leal RuizTaking people
- Cahaba Derm and skin hlth ctr 27Birmingham, United StatesContact: Wes BoothTaking people
- Hamzavi DermatologyFort Gratiot, United StatesContact: Lee CampbellTaking people
- First OC DermatologyFountain Valley, United StatesContact: Keiry EspinozaTaking people
- Endeavor HealthGlenview, United StatesContact: Jalen CoreyTaking people
- Encore Medical ResearchHollywood, United StatesContact: Yeniska HallTaking people
- Center for Clinical StudiesHouston, United StatesContact: Perla RivasTaking people
- Dawes Fretzin Clinical Rea GroupIndianapolis, United StatesContact: Michelle RiggsTaking people
- Mayo Clinic- JacksonvilleJacksonville, United StatesContact: Jarell C HughesTaking people
- Las Vegas DermatologyLas Vegas, United StatesContact: Faith LimonTaking people
- Miami Derm and Laser InstituteMiami, United StatesContact: Swanee CeperoTaking people
- International Clinical Research Tennessee LCCMurfreesboro, United StatesContact: Eris SteeleTaking people
- Virginia Clinical ResearchNorfolk, United StatesContact: Crystal TempleTaking people
- Skin Specialists, PCOmaha, United StatesContact: Schyler SchrieverTaking people
- Austin Inst for Clinical ResearchPflugerville, United StatesContact: Tolga HanTaking people
- ACRC TrialsPlano, United StatesContact: Jani TaylorTaking people
- Oregon Medical Research CenterPortland, United StatesContact: Megan LameyTaking people
- DermAssociates, LLCRockville, United StatesContact: Meheret AfeworkTaking people
- MedDerm AssociatesSan Diego, United StatesContact: Kristian CadagTaking people
- Global Clinical ProfessionalsSt. Petersburg, United StatesContact: Madelaine PerezTaking people
- Equity MedicalThe Bronx, United StatesContact: Luana CabrejaTaking people
- Clinical Trials Research InstituteThousand Oaks, United StatesContact: Shawn AhoubimTaking people
- Revival Research InstituteTroy, United StatesContact: Madhuri ParaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT07431177EU 2025-522301-37-00
- Record updated
- 9 November 2026
- Original description
The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632 in participants with NSV and to identify the optimal dose to be promoted into the confirmatory Phase 3 program.Read full original descriptionShow less
A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase IIb Study to Assess the Efficacy and Safety of GIA632 in Adult Participants With Non-segmental Vitiligo Followed by an Extension Period
The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632 in participants with NSV and to identify the optimal dose to be promoted into the confirmatory Phase 3 program.
Inclusion: Signed informed consent must be obtained prior to participation in the study; Male or female as assigned at birth ≥ 18 years of age at the time of screening; Individuals with a diagnosis of non-segmental vitiligo and confirmation of diagnosis through physical examination by the investigator; Non-segmental vitiligo, as assessed at screening, as; ≥ 0.5% Body Surface Area (BSA) on the face and F-VASI score ≥ 0.5; ≥ 3% BSA on non-facial areas (minimum of 3% should be calculated in addition to hands and feet) and T-VASI score = 3 to 60.
Exclusion: Previous exposure to biologic drugs directly targeting IL-15 or IL-15 receptors; Individual who previously attempted or completed depigmentation therapy for NSV; Use of prohibited medication \& treatments. Other protocol-defined inclusion/exclusion criteria may apply; Presence of segmental or mixed vitiligo, or other skin comorbidities that may interfere with study assessments (e.g., hypopigmented mycosis fungoides, genetic diseases with pigmentary aberrations [such as piebaldism, Waardenburg, etc.], chemical- or druginduced leukoderma, etc.); Individuals unable or unwilling to follow the study procedures and/or to complete the study-related questionnaires.